At the news
? BULLISHIMPACT 8/10 8-K filed Apr 6, 2026 at 07:35 ET
Neurocrine Biosciences (NBIX) has entered into a definitive agreement to acquire Soleno Therapeutics (SLNO) for $53.00 per share in cash, representing a total equity value of $2.9 billion. The acquisition will add VYKATTM XR, the first and only FDA-approved treatment for hyperphagia in Prader-Willi syndrome, to Neurocrine's portfolio of first-in-class medicines, strengthening its leadership in endocrinology and rare disease. The deal is expected to close within 90 days, subject to customary closing conditions including regulatory approvals.
- Neurocrine Biosciences is acquiring Soleno Therapeutics for $53.00 per share in cash.
- The total transaction equity value is $2.9 billion.
- The acquisition adds VYKATTM XR, the first and only FDA-approved treatment for hyperphagia in Prader-Willi syndrome, to Neurocrine's portfolio.
- VYKATTM XR generated $190 million in revenue for Soleno in 2025.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access